The antibiotic teixobactin—developed a decade ago by Northeastern University professors Kim Lewis and Slava Epstein in ...

The intravenous options for MRSA are generally limited to vancomycin ... inhaled and intravenous antibiotic agents. Chronic use of aerosolized antibiotics such as tobramycin or colistin, as ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive ...

MRSA - or methicillin resistant staphylococcus aureus - has already become resistant to most common antibiotics, making it difficult to treat with drugs. Once it gets into the body, through wounds ...

According to the Centers for Disease Control and Prevention (CDC), chlorine can kill methicillin-resistant Staphylococcus aureus (MRSA). If the chlorine and pH levels are correct, MRSA cannot ...

aureus (MRSA). The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole’s revenues, according to analysts. In 2023 ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...